Slow-cycling/dormant cancer cells (SCCs) have pivotal roles in driving cancer relapse and drug resistance. A mechanistic explanation for cancer cell dormancy and therapeutic strategies targeting SCCs are necessary to improve patient prognosis, but are limited because of technical challenges to obtaining SCCs. Here, by applying proliferation-sensitive dyes and chemotherapeutics to non–small cell lung cancer (NSCLC) cell lines and patient-derived xenografts, we identified a distinct SCC subpopulation that resembled SCCs in patient tumors. These SCCs displayed major dormancy-like phenotypes and high survival capacity under hostile microenvironments through transcriptional upregulation of regulator of G protein signaling 2 (RGS2). Database analysis revealed RGS2 as a biomarker of retarded proliferation and poor prognosis in NSCLC. We showed that RGS2 caused prolonged translational arrest in SCCs through persistent eukaryotic initiation factor 2 (eIF2α) phosphorylation via proteasome-mediated degradation of activating transcription factor 4 (ATF4). Translational activation through RGS2 antagonism or the use of phosphodiesterase 5 inhibitors, including sildenafil (Viagra), promoted ER stress–induced apoptosis in SCCs in vitro and in vivo under stressed conditions, such as those induced by chemotherapy. Our results suggest that a low-dose chemotherapy and translation-instigating pharmacological intervention in combination is an effective strategy to prevent tumor progression in NSCLC patients after rigorous chemotherapy.
In conventional stem cell transplantation therapies for ischemic limb diseases, stem cells are generally transplanted into the ischemic region (IR), and most of the transplanted cells undergo hypoxia-mediated cell death. Due to the massive cell death, the therapeutic efficacy is reduced and a high dose of stem cells is necessitated for the therapies. Here, we investigated whether the therapeutic efficacy can be improved and the cell dosage can be reduced in the therapy for limb ischemia simply by modifying stem cell injection site to a site where the cell engraftment is improved and blood vessel sprouting is efficiently stimulated. Human mesenchymal stem cells (hMSCs) cultured under hypoxic condition, which simulate cells transplanted to IR, underwent extensive cell death in vitro. Importantly, the cell death was significantly attenuated when hMSCs adhered first under normoxic condition for 24 h and then were exposed to hypoxic condition, which simulates cells transplanted to the border zone (BZ) in the upper thigh and migrated to IR. hMSCs at doses of 2×105 or 2×106 cells were injected into the IR or BZ of the five-week-old female athymic mice after ischemic hindlimb induction. Compared to hMSC transplantation to the IR of mouse ischemic limbs, transplantation to the BZ significantly enhanced cell engraftment and paracrine factor secretion, which effectively stimulated vessel sprouting, enhanced blood perfusion in IR, and enabled the cell dosage reduction. Therefore, the modification of the stem cell transplantation site would improve the current stem cell therapies for ischemic limb diseases in terms of cell dosage reduction and therapeutic efficacy enhancement.
Skin tissue engineering has emerged as a promising therapeutic strategy for severe wounds and inflammatory skin diseases. Stem cell-derived exosomes (SC-Exos) have recently gained increasing attention as cell-free therapeutic agents with regenerative and immunomodulatory potential, offering possible advantages over direct stem cell transplantation. To fully realize their therapeutic potential, however, efficient delivery platforms are needed to enhance local retention, preserve vesicle integrity, and support sustained release within the diseased skin microenvironment. In this review, we discuss advanced polymeric biomaterials as functional delivery platforms for SC-Exos in skin tissue engineering. We focus on natural and synthetic polymers engineered into nanofibrous scaffolds, hydrogels, and microneedles, and examine how these systems enhance exosome loading, protect vesicle integrity, improve local retention, and modulate release kinetics. We further highlight the therapeutic effects and underlying mechanisms of polymer–exosome systems in skin lesion repair, focusing on their roles in promoting angiogenesis, modulating local inflammation and immune responses, and facilitating extracellular matrix remodeling. Finally, we address remaining challenges and future directions for translating polymer-based SC-Exos delivery platforms into clinically relevant skin regenerative therapies.